Product review · Updated November 8, 2026
Veozah review: trial evidence, safety and complaints
A guide to reading Veozah reviews: questions to ask about evidence, unwanted effects and ongoing care, with current and historical sources clearly identified.
Public-source editorial research · No clinician sign-off or firsthand treatment testing
A day interrupted by repeated heat episodes and a night of unsatisfying sleep may be connected, but improvement in one does not automatically prove improvement in the other. Veozah is the brand of fezolinetant reviewed here. Its US label concerns moderate to severe vasomotor symptoms due to menopause, rather than a general promise to restore sleep or energy.
We reviewed the official prescribing information and primary trial reports on September 29, 2026. The current label is revised February 2026 and includes a boxed warning about liver injury. This review separates what the studies counted, what participants reported about sleep, and what clinical safety responsibility remains. It provides no individual medicine recommendation, dose instruction or laboratory timetable.
Veozah treats a defined menopausal symptom category. A secondary sleep finding does not create an insomnia indication or remove current liver-safety requirements.
In this article
1. Define the goal before interpreting a result
The Veozah indication is specific to menopausal vasomotor symptoms. It does not diagnose the reason someone wakes at night. A count of heat episodes, how disruptive they feel and the experience of sleeping are related subjects that can still require separate assessment. NIA's menopause and sleep guidance describes several contributors to poor sleep and advises discussing continuing difficulties with a clinician.
The guide to frequency, severity and impact develops this distinction. A person whose hot flashes become less frequent may still have an important sleep concern. That remaining concern should not disappear merely because one trial outcome improved on average.
2. The pivotal label evidence used two symptom measures
In the label's clinical studies, two trials evaluated changes in moderate to severe vasomotor-symptom frequency and severity at weeks four and twelve against placebo. Both measures favored the studied Veozah group at those assessments. Frequency described how often symptoms occurred; severity described a different feature of those symptoms. These were group comparisons, not guarantees about a particular patient's day or night.
The placebo-controlled efficacy period was followed by a treatment extension. It would be inaccurate to describe that entire later period as an unchanged placebo comparison. The Lynkuet review examines another trial program whose follow-up design also needs to be distinguished from its initial comparison period.
3. DAYLIGHT adds a qualified sleep finding
The primary DAYLIGHT publication studied 453 participants considered unsuitable for hormone therapy for several different reasons, including caution or preference as well as contraindication. It compared fezolinetant with placebo over 24 weeks. The primary endpoint was vasomotor-symptom frequency; patient-reported sleep disturbance was a secondary outcome.
At week 24, the sleep score favored fezolinetant, with a reported between-group difference of 2.5 points in the direction of less disturbance. The paper explicitly says the sleep P values were not adjusted for multiple comparisons. That qualification belongs with the finding. The manufacturer, Astellas, funded the study. Neither the score nor its statistical result establishes an approved insomnia treatment or predicts an individual's sleep improvement.
4. Do not compare unlike sleep scores as a league table
DAYLIGHT's sleep assessment asked participants about difficulties and perceptions of their sleep. It did not measure every cause of waking or objectively prove restorative sleep. Its predominantly white population and defined treatment-selection criteria also limit broad assumptions about who the results represent.
The Brisdelle review discusses a different analysis of awakenings that participants attributed to vasomotor symptoms. Those counts cannot be ranked directly against a questionnaire score from a different trial. Our night-sweats and sleep guide keeps the underlying questions separate: fewer heat episodes, fewer awakenings, easier sleep onset and better daytime functioning are not interchangeable claims.
5. Earlier trial reassurance does not replace the current warning
DAYLIGHT reported no drug-induced liver injury in its study population. The current Veozah label, however, contains a boxed warning following liver injury reported after marketing. Both statements can be true because a clinical trial is not the whole subsequent safety record. The current label requires liver evaluation before treatment and continued testing during treatment, with decisions managed by the treating clinician.
It directs patients to stop Veozah and seek medical attention if symptoms suggest liver injury, such as new fatigue, poor appetite, nausea, itching, jaundice, dark urine, pale stools or abdominal pain. This urgent labeled instruction should remain visible; the article does not substitute a personal monitoring calendar or interpret someone's laboratory results.
6. The medicine list and daytime experience still matter
The label lists contraindications involving known cirrhosis, severe kidney impairment or end-stage kidney disease, and use of CYP1A2 inhibitors. These are product-specific restrictions, not a complete self-screening tool. A clinician and pharmacist need the actual medicine list and relevant history. Veozah's common adverse reactions also include insomnia, which makes a universal better-sleep promise particularly inappropriate.
The nonhormonal risk guide explains why the absence of estrogen does not mean the absence of important precautions. Report the experience that matters, including persistent sleep disruption or unwanted effects, rather than assuming any change in alertness is evidence that treatment is working.
7. Evidence does not supply a purchase or follow-up plan
A prescribing label does not tell us a person's copayment, a pharmacy's present stock or whether a specific clinic will prescribe the product. No purchase, insurance claim or clinical visit was tested for this review. Those practical questions need a separate, selected care arrangement with someone responsible for safety testing and follow-up.
The claim checklist helps ask what an offer actually includes. A useful reassessment returns to both the daytime concern and the nighttime concern, without demanding that they improve identically. The strongest supported conclusion is limited: Veozah has evidence for its labeled vasomotor goal and a qualified secondary sleep finding, alongside current safety obligations that cannot be omitted.
The Allara review illustrates the separate task of checking a documented care service: a clinic description does not itself verify access to this product or its trial outcomes.
8. Reading Veozah and fezolinetant reviews and complaints
Is this a patient-review score?
No. This is a public-document review. We have not verified a representative set of patient experiences or measured a complaint rate. Its purpose is to make the evidence and unanswered questions easier to find, not to award stars or suggest that every reader should expect the same result.
How should I interpret a reported side effect?
Compare the concern with the current prescribing information and discuss your own experience with the treating clinician. Veozah's boxed warning addresses liver injury. A reassuring testimonial does not cancel that warning, and an online complaint cannot establish what caused an individual event. Section 5 preserves the labeled urgent response to possible liver-injury symptoms.
Does a positive review show that the medicine will work for me?
A personal account can help identify a question you want answered. It does not supply the comparison, follow-up or clinical assessment needed to predict your own result. Ask what changed, what remained difficult, how long the person was followed and whether the account concerns the medicine or a service. Those details are more useful than treating every use of the word “review” as the same kind of evidence.
9. Turn a broad review claim into a follow-up question
Choose the part of the claim that matters most to your decision: symptom relief, an unwanted effect, access to care or the bill. Write that part as a question for the person responsible for it. A request about an invoice and a concern about treatment should not disappear into the same general satisfaction score.
- Which outcome is the claim describing?
- What comparison supports it, and what information is missing?
- Who will review my own concerns and any required results?
- Which charges and follow-up arrangements have actually been explained to me?
Our SKYLIGHT 1 analysis provides a fuller reading of one study, while the care-claim checklist helps examine a service description. The night-sweats guide offers a way to describe the nighttime concern. Use those links for their stated questions; they do not supply a personal purchase or prescribing plan.
10. Sources refreshed for the November update
On November 8, 2026, we rechecked the Veozah label and read the full DAYLIGHT article through Europe PMC. The original September references remain in place and retain their earlier dates. A new access date describes the recheck; it does not change when a study was conducted or when its findings were published.
The NIA page was unavailable for a fresh read during this update, so its historical source record remains explicitly dated. We did not interview patients, investigate individual complaints, test a purchase or confirm personal insurance coverage. The review therefore continues to separate published evidence from questions that only an individual care arrangement can resolve.
Source notes
References support the claims beside them. Provider pages describe an offer; they do not demonstrate treatment outcomes.
- Veozah (fezolinetant) US prescribing informationExact official DailyMed label. Revised February 2026; boxed hepatotoxicity warning; same-day official HTML record reviewed with original timestamp · Checked 2026-09-29
- NIA: sleep problems and menopausePatient guidance, content reviewed September 30, 2021; multiple contributors and distinct insomnia assessment · Checked 2026-09-29
- Fezolinetant: DAYLIGHT phase 3b randomized trialPrimary placebo-controlled 24-week study; secondary sleep P values not multiplicity controlled; Astellas funding; current label controls safety · Checked 2026-09-29
- Veozah prescribing information: November checkOfficial label revised February 2026; freshly accessed, with earlier records retained. · Checked 2026-11-08
- DAYLIGHT full article: November checkFull primary article accessed through Europe PMC for this update. · Checked 2026-11-08